Abstract: 6-Sulfanilamidoindazole (6SAI) is a sulfonamide that induces acute, self-limiting arthritis in rats, and it is reported that endotoxin may modify the sensitivity to 6SAI in rats. In this study, detailed pathological changes were examined in lipopolysaccharide (LPS)-hyporesponsive C3H/HeJ (Lps d ) and LPS-normoresponsive C3H/HeN (Lps n ) mice orally administered with 6SAI (500, 1000 mg/kg) daily for 2 wk. There was no joint swelling observed in any animals treated with 6SAI. Histopathologically, 6SAI-treated mice from both strains showed the same changes such as hypertrophy of hepatocytes, mural thickening of hepatic artery, thickening of adrenal cortex, hypertrophy of thyroid epithelium and hypertrophy of intestinal mucosa. In one animal of the high-dose group of C3H/HeJ strain showed focal epicarditis and capsulitis of thymus and lungs. In the synovium of tarsal joints, there were no changes observed in any 6SAI-treated animals. From this study, it is confirmed that hepatic artery, hepatocytes, thyroid epithelium and intestinal mucosa are target sites of 6SAI in mice. 6SAI-induced toxicity in mice is considered not to be correlated with LPS sensitivity. (J Toxicol Pathol 2001; 14: 169-172) Key words: 6-sulfanilamidoindazole, histopathology, mouse, strain difference 6-Sulfanilamidoindazole (6SAI), an antibacterial sulfonamide, is known to induce an acute, self-limiting arthritis and periarthritis mainly in hind paws of rats [1] [2] [3] [4] , and it is reported that endotoxin may influence the susceptibility to 6 SAI in r ats 5 , 6 . On th e ot he r h a nd , s ys te m ic histopathological examinations on mice treated with 6SAI have not yet been carried out. Therefore, this study was carried out to clarify the systemic histopathology of 6SAI-treated mice and the relationship between LPS sensitivity and 6SAI-induced toxicity using lipopolysacchride (LPS)-hyporesponsive C3H/HeJ (Lps d ) and LPS-normoresponsive C3H/HeJ (Lps d ) mice. 6SAI was obtained from Aldrich Japan, Inc. (Tokyo). The compound was suspended in 1.0% carboxymethylcellulose before daily use.
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Six-week-old male C3H/HeJ Jcl mice and C3H/HeN Jcl mice (CLEA Japan,Inc., Tokyo ) were used. They were kept in an animal room controlled at a temperature of 23 ± 1°C and a relative humidity of 55 ± 5% with a 12 hour light-dark cycle, and fed standard commercial laboratoy diet (CRF1, Charles River Japan Inc., Kanagawa) and tap water ad libitum.
The animals were orally administered with 6SAI at the dose levels of 0, 500 and 1000 mg/kg/day (n=6 in each group of each strain) for 2 weeks. The animals were observed daily and body weights were recorded twice a week. At the end of study, the animals were killed by exsanguination under ether anesthesia. Blood samples obtained from each animal were used for hematological and serum biochemical analyses. Major organs and tissues were removed and then fixed in 10% neutral buffered formalin. Paraffin sections at 5 µm were stained with hematoxylin and eosin (HE) and subjected to histopathological examinations.
In the 6SAI-treated groups, no apparent changes were observed in body weight gain and general conditions. No paw swelling was noticed in the 6SAI-treated mice. Hematological examination revealed that the high-dose group of C3H/HeN strain showed a slight decrease in red blood cell count. Fibrinogen value, which was reported to correspond with joint inflammation in the 6SAI-treated rats 4 , showed no changes in any treated-groups. In blood biochemistry, 6SAI caused an increase in triglyceride, and decreases in total cholesterol, urea nitrogen, total protein and albumin in both strains. In rats, 6SAI caused a decrease in triglyceride and an increase in total cholesterol 4 . These findings indicate that the effects of 6SAI on lipid metabolism may be different between rats and mice.
Histopathologically, the 6SAI-treated animals in both stra ins showed mild to m oder ate hype rtrophy of centrilobular hepatocytes, mild thickening of zona fasciculata in the adrenal glands, mild to moderate hypertrophy of thyroid epithelium and mild hypertrophy of intestinal mucosa (Table 1 , and Fig. 1 ). In addition, mural thickening and luminal dilation of small-sized arteries in the portal region were observed in the high-dose group of both strains (Fig. 2) . In one animal of C3H/HeJ strain, focal capsular inflammation with fibrosis in the lungs and thymus, and focal epicarditis were also noted.
Our previous study showed that 6SAI induced arthritis/ periarthritis in tarsal and other joints, arteritis and serositis in several oragans and tissues, hypertrophy of thyroid epithelium, and enlargement of adrenal glands in rats 4 . Especially, the arterial changes in the 6SAI-treated rats were detected primarily in the liver, and the changes including medial fibrinoid degeneration were followed by medial hypertrophy and periarterial fibrosis, and sometimes accompanied with intimal thickening 4 . Taken together with the 6SAI-induced histopathologic changes in rats 4 , the arterial changes in the liver, hypertrophy of thyroid epithelium and mild thickening of adrenal cortex were considered to be the common toxicity of 6SAI to rats and mice. Although the pathogenesis of the arterial changes observed in 6SAI-treated mice and rats is still obscure, it is interesting that arteries in the liver were the target site of 6SAI-toxicity. In addition, serositis, such as focal capsular inflammation with fibrosis in the lungs and thymus, and focal epicarditis which was seen in one animal treated with 6SAI in this study may also be related with 6SAI toxicity, because the similar changes were frequently observed in the 6SAI-treated rats 4 . However, it is difficult to distinguish these changes from spontaneous changes at the present.
Bronchopneumonia which is reported to be frequently observed in the 6SAI-treated mice 1 was never seen in this study.
The thyroid effects seen in both species were thought to be due to an inhibition of thyroid hormone syntehsis, because it is well known that 6SAI is metabolized into sulfonamide 7 . Other changes observed in this study, such as hypertrophy of centrilobular hepatocytes and hypertrophy of intestinal mucosa, indicate that these tissues were also target organs of 6SAI in mice. Histopathological changes observed in this study on mice were considered to be almost the same in the nature but a little different in the degree between two strains. In addition, there is no apparent relationship between LPS sensitivity and 6SAI-induced toxicity in mice.
In conclusion, it was revealed that there were species differences in the toxicity of 6SAI between mice and rats, although, at least two organs, i.e. arteries in the liver and thyroid glands, were considered to be common target sites of 6SAI toxicity in these two rodent species. It was also reconfirmed that mice was insensitive against 6SAI-induced arthritis, and that the toxicity of 6SAI in mice was not correlated with LPS sensitivity. 
